Terms: = Pancreatic cancer AND DAXX, BING2, 1616, ENSG00000206206, MGC126246, Q9UER7, MGC126245, DAQB-126H3_2, DAP6 AND Clinical Outcome
329 results:
1. Tumor-Stroma Proportion to Predict Chemoresistance in Patients With Ovarian cancer.
Lou E; Clemente V; Grube M; Svedbom A; Nelson AC; Blome F; Staebler A; Kommoss S; Bazzaro M
JAMA Netw Open; 2024 Feb; 7(2):e240407. PubMed ID: 38411963
[TBL] [Abstract] [Full Text] [Related]
2. Somatostatin receptor 2 (SSTR2) expression is associated with better clinical outcome and prognosis in rectal neuroendocrine tumors.
Kim JY; Kim J; Kim YI; Yang DH; Yoo C; Park IJ; Ryoo BY; Ryu JS; Hong SM
Sci Rep; 2024 Feb; 14(1):4047. PubMed ID: 38374188
[TBL] [Abstract] [Full Text] [Related]
3. Locally advanced pancreatic cancer: Is surgical palliation associated with improved clinical outcome relative to medical palliation?
Kramer SP; Tonelli C; Luchette FA; Swanson J; Abdelsattar Z; Cohn T; Baker MS
Am J Surg; 2024 Apr; 230():73-77. PubMed ID: 38350746
[TBL] [Abstract] [Full Text] [Related]
4. A novel investigation into the negative impact of opioid use on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer patients.
Guo H; Li Y; Lin J; Li D; Yang J; Wang J; Mao J; Wang Y; Yan X
Int Immunopharmacol; 2024 Mar; 129():111611. PubMed ID: 38325047
[TBL] [Abstract] [Full Text] [Related]
5. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract] [Full Text] [Related]
6. APOBEC3C is a novel target for the immune treatment of lower-grade gliomas.
Zhao S; Li Y; Xu J; Shen L
Neurol Res; 2024 Mar; 46(3):227-242. PubMed ID: 38007705
[TBL] [Abstract] [Full Text] [Related]
7. Optimal Follow-up of Incidental pancreatic Cystic Lesions without Worrisome Features: clinical outcome after Long-term Follow-up.
Ahn DW; Lee SH; Choi JH; Cho IR; Jang DK; Paik WH; Jeong JB; Ryu JK; Kim YT
Gut Liver; 2024 Mar; 18(2):328-337. PubMed ID: 37840221
[TBL] [Abstract] [Full Text] [Related]
8. Response of Locally Advanced pancreatic cancer to Intratumoral Injection of Large Surface Area Microparticle Paclitaxel: Initial Report of Safety and clinical outcome.
Sharma NR; Lo SK; Hendifar A; Othman MO; Patel K; Mendoza-Ladd A; Verco S; Maulhardt HA; Verco J; Wendt A; Marin A; Schmidt CM; diZerega G
Pancreas; 2023 Mar; 52(3):e179-e187. PubMed ID: 37782888
[TBL] [Abstract] [Full Text] [Related]
9. clinical outcomes and response to chemotherapy in a cohort of pancreatic cancer patients with germline variants of unknown significance (VUS) in BRCA1 and BRCA2 genes.
Militello AM; Orsi G; Cavaliere A; Niger M; Avallone A; Salvatore L; Tortora G; Rapposelli IG; Giordano G; Noventa S; Giommoni E; Bozzarelli S; Macchini M; Peretti U; Procaccio L; Puccini A; Cascinu S; Montagna C; Milella M; Reni M
Cancer Chemother Pharmacol; 2023 Dec; 92(6):501-510. PubMed ID: 37725113
[TBL] [Abstract] [Full Text] [Related]
10. clinical outcome and therapeutic impact on neuroendocrine neoplasms of the breast: a national cancer database study.
Yang L; Lin H; Shen Y; Roy M; Albarracin C; Ding Q; Huo L; Chen H; Wei B; Bu H; Bedrosian I; Wu Y
Breast Cancer Res Treat; 2023 Nov; 202(1):23-32. PubMed ID: 37566192
[TBL] [Abstract] [Full Text] [Related]
11. Ampullary cancer: Histological Subtypes, Markers, and clinical Behaviour-State of the Art and Perspectives.
Nappo G; Funel N; Laurenti V; Stenner E; Carrara S; Bozzarelli S; Spaggiari P; Zerbi A
Curr Oncol; 2023 Jul; 30(7):6996-7006. PubMed ID: 37504367
[TBL] [Abstract] [Full Text] [Related]
12. Personalized cancer avatars for patients with thymic malignancies: A pilot study with circulating tumor cell-derived organoids.
Wu YH; Chao HS; Chiang CL; Luo YH; Chiu CH; Yen SH; Liu CY; Chiou JF; Burnouf T; Chen YJ; Wang PY; Chao TY; Hsu SM; Lu LS
Thorac Cancer; 2023 Sep; 14(25):2591-2600. PubMed ID: 37474689
[TBL] [Abstract] [Full Text] [Related]
13. Prognostic value of perioperative serum low-density lipoprotein cholesterol level for postoperative prognosis of pancreatic cancer: a retrospective study.
Wang H; Li Y; Huang J; Ma Y; Lyu S; Lang R
Lipids Health Dis; 2023 Jun; 22(1):88. PubMed ID: 37391827
[TBL] [Abstract] [Full Text] [Related]
14. The Feasibility, Proficiency, and Mastery Learning Curves in 635 Robotic Pancreatoduodenectomies Following a Multicenter Training Program: "Standing on the Shoulders of Giants".
Zwart MJW; van den Broek B; de Graaf N; Suurmeijer JA; Augustinus S; Te Riele WW; van Santvoort HC; Hagendoorn J; Borel Rinkes IHM; van Dam JL; Takagi K; Tran KTC; Schreinemakers J; van der Schelling G; Wijsman JH; de Wilde RF; Festen S; Daams F; Luyer MD; de Hingh IHJT; Mieog JSD; Bonsing BA; Lips DJ; Abu Hilal M; Busch OR; Saint-Marc O; Zeh HJ; Zureikat AH; Hogg ME; Koerkamp BG; Molenaar IQ; Besselink MG;
Ann Surg; 2023 Dec; 278(6):e1232-e1241. PubMed ID: 37288547
[TBL] [Abstract] [Full Text] [Related]
15. High expression of PKCλ and ALDH1A3 indicates a poor prognosis, and PKCλ is required for the asymmetric cell division of ALDH1A3-positive cancer stem cells in PDAC.
Kasai T; Tamori S; Takasaki Y; Matsuoka I; Ozaki A; Matsuda C; Harada Y; Sasaki K; Ohno S; Akimoto K
Biochem Biophys Res Commun; 2023 Aug; 669():85-94. PubMed ID: 37267864
[TBL] [Abstract] [Full Text] [Related]
16. Epigenetic upregulation of MNAT1 by SMYD2 is linked to PI3K/AKT activation and tumorigenesis of pancreatic adenocarcinoma.
Xu Z; Liu Y; Pan Z; Qin L
Histol Histopathol; 2024 Feb; 39(2):263-277. PubMed ID: 37232506
[TBL] [Abstract] [Full Text] [Related]
17. An Inflection Point in cancer Protein Biomarkers: What was and What's Next.
Barker AD; Alba MM; Mallick P; Agus DB; Lee JSH
Mol Cell Proteomics; 2023 Jul; 22(7):100569. PubMed ID: 37196763
[TBL] [Abstract] [Full Text] [Related]
18. Biological evaluation of novel gemcitabine analog in patient-derived xenograft models of pancreatic cancer.
Inkoom A; Ndemazie NB; Smith T; Frimpong E; Bulusu R; Poku R; Zhu X; Han B; Trevino J; Agyare E
BMC Cancer; 2023 May; 23(1):435. PubMed ID: 37179357
[TBL] [Abstract] [Full Text] [Related]
19. Smaller panel, similar results: genomic profiling and molecularly informed therapy in pancreatic cancer.
Reissig TM; Tzianopoulos I; Liffers ST; Rosery VK; Guyot M; Ting S; Wiesweg M; Kasper S; Meister P; Herold T; Schmidt HH; Schumacher B; Albers D; Markus P; Treckmann J; Schuler M; Schildhaus HU; Siveke JT
ESMO Open; 2023 Jun; 8(3):101539. PubMed ID: 37148593
[TBL] [Abstract] [Full Text] [Related]
20. FAP-targeted CAR-T suppresses MDSCs recruitment to improve the antitumor efficacy of claudin18.2-targeted CAR-T against pancreatic cancer.
Liu Y; Sun Y; Wang P; Li S; Dong Y; Zhou M; Shi B; Jiang H; Sun R; Li Z
J Transl Med; 2023 Apr; 21(1):255. PubMed ID: 37046312
[TBL] [Abstract] [Full Text] [Related]
[Next]
